Clinical Trials | March 03, 2026
AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients
This study evaluated a difficult-to-treat Crohn's disease patient population
This study evaluated a difficult-to-treat Crohn's disease patient population
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Desmopressin Acetate Injection is primarily used to treat central diabetes insipidus, haemophilia A, and von Willebrand disease
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
Subscribe To Our Newsletter & Stay Updated
